Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 7/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6847495 | 0.91 | CYP11B1 (0.42) | HTR1DHTR7CYP19A1CYP2A6MAPT | |
| SCHEMBL6659505 | 0.87 | HTR6 (0.50) | HTR1DCYP19A1HTR6MAPTCYP11B1 | |
| SCHEMBL6658554 | 0.81 | CYP19A1 (0.48) | HTR1DCYP19A1HTR6MAPTCYP11B1 | |
| SCHEMBL6663540 | 0.81 | MAPT (0.44) | CYP19A1HTR6MAPTCYP11B1CYP11B2 | |
| SCHEMBL6840679 | 0.81 | CYP11B1 (0.52) | CYP19A1HTR6MAPTCYP11B1CYP11B2 | |
| SCHEMBL6845462 | 0.80 | MAPT (0.49) | CYP19A1HTR6MAPTCYP17A1CYP3A4 | |
| SCHEMBL6845508 | 0.79 | CYP2A6 (0.50) | HTR1DHTR7CYP19A1HTR6CYP2A6 | |
| SCHEMBL6659317 | 0.79 | CYP19A1 (0.45) | HTR1DCYP19A1HTR6MAPTCYP17A1 | |
| SCHEMBL6845500 | 0.77 | CYP11B1 (0.47) | CYP19A1HTR6MAPTCYP11B1CYP11B2 | |
| SCHEMBL6846187 | 0.75 | MAPT (0.40) | CYP19A1MAPTCYP17A1BACE1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2004-11-25 | — | — | US | disclosed |
| EP-1432698-A2 | SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003027094-A2 | SUBSTITUTED 3-PYRIDYL INDOLES AND INDAZOLES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | CYP17A1, IDO1, CYP21A2 | HTR1D 1156/4885HTR7 979/4885CYP19A1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.